AZ grabs EU approval for Imfinzi in advanced lung cancerThe European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was Share XAZ grabs EU approval for Imfinzi in advanced lung cancerhttps://pharmaphorum.com/news/az-grabs-eu-approval-for-imfinzi-in-advanced-lung-cancer/
Patients call for end to CF drug price row at key meetingRepresentatives of NHS England and cystic fibrosis drug company Vertex are to meet on Thursday to try and Share XPatients call for end to CF drug price row at key meetinghttps://pharmaphorum.com/news/patients-call-for-cf-drug-price-agreement-ahead-of-meeting/
Novartis to cut 2,200 jobs in Switzerland to boost profitsNovartis has announced that it will cut 2,200 jobs in Switzerland to boost its profitability. The company told Share XNovartis to cut 2,200 jobs in Switzerland to boost profitshttps://pharmaphorum.com/news/novartis-to-cut-2200-jobs-in-switzerland-to-boost-profits/
Gilead launches generics of own hepatitis C drugs in US to cut health costsGilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls Share XGilead launches generics of own hepatitis C drugs in US to cut health costshttps://pharmaphorum.com/news/gilead-launches-generics-of-own-hepatitis-c-drugs-in-us-to-cut-health-costs/
Merck and Pfizer trial cancer combination with Australia’s ImmutepAustralian biotech Immutep has begun a clinical trial partnership with Germany’s Merck KGaA and Pfizer to develop a Share XMerck and Pfizer trial cancer combination with Australia’s Immutephttps://pharmaphorum.com/news/merck-and-pfizer-trial-cancer-combination-with-australias-immutep/
Roche aims to improve cancer treatments with DNA blood testRoche has launched a blood test that can identify 70 of the most commonly mutated genes in solid Share XRoche aims to improve cancer treatments with DNA blood testhttps://pharmaphorum.com/news/roche-aims-to-improve-cancer-treatments-with-dna-blood-test/
Public inquiry investigates thousands of deaths from infected NHS bloodA public inquiry has opened to look into how infected NHS blood killed more than 2,900 people since Share XPublic inquiry investigates thousands of deaths from infected NHS bloodhttps://pharmaphorum.com/news/public-inquiry-investigates-thousands-of-deaths-from-infected-blood-on-nhs/
Underinvestment in medtech threatens sector growth – EYUnderinvestment in medical technology could threaten growth in the sector, according to a report by Ernst & Young Share XUnderinvestment in medtech threatens sector growth – EYhttps://pharmaphorum.com/digital/underinvestment-in-medtech-threatens-sector-growth-ey/
Study shows AZ’s Farxiga diabetes drug cuts heart risksAstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in Share XStudy shows AZ’s Farxiga diabetes drug cuts heart riskshttps://pharmaphorum.com/news/study-shows-azs-farxiga-diabetes-drug-cuts-heart-risks/
